Trial Profile

A Phase 2a proof of concept (POC), open-label, multicenter trial evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed prior anti-cancer therapy regimen

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2021 New trial record
18 Jan 2021 According to a Propanc Biopharma media release, the company looks forward to a potential collaboration with the clinical trial investigator Dr Natalia Luque Caro from the University Hospital of Jaen, in Granada, Spain, for this study.
18 Jan 2021 According to a Propanc Biopharma media release, this study is planned to begin shortly after the completion of Phase 1b FIH study. This study is hoped to finalized in 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com